TORONTO, ON, CANADA (Jul 10, 2018) - Cyclica Inc. is pleased to announce the appointment of Dr. Mostafa Analoui, Ph.D. as Chairman of its Board of Directors (BoD).
Dr. Analoui has been a member of the BoD since October 2016, and has brought to Cyclica deep expertise in the pharmaceutical industry, and in venture capital investment strategies.
Naheed Kurji, Cyclica’s President and CEO, had this to say, “I want to thank our outgoing Chairman, George Bickerstaff, who, over the past 5 years, has provided valuable advisory and governance leadership to Cyclica. Looking forward, I am thrilled to work more closely with Mostafa, someone for whom I have significant deference, especially since he joined the BoD in October 2016. At all levels of the organization, we seek to attract those that roll up his sleeves and help progress the company in various ways, and I can’t think of a better person than Mostafa.”
Mostafa stated that, “It has been exciting watching Cyclica grow over the past few years, and more formally supporting their growth since I joined the BoD. The company has the potential of changing how scientists interact with and rely cloud-based technologies, and in doing so transform pharma productivity for the betterment of patients. I see the potential in Cyclica’s vision, and am thrilled to participate more intimately in the company’s growth in this new role.”
About Mostafa Analoui: Dr. Analoui is the Executive Director of UConn Venture Development at the University of Connecticut. Prior to that Dr. Analoui served as Head of Healthcare and Life Science at The Livingston Securities. He also served as the Senior Director and the Groton/New London Site Head for Global Clinical Technology of Pfizer Inc. Global Research and Development from 2001 to February 2008, where he led the platform technology mission for the clinical development and commercial division in areas including computational medicine. He is also an Adjunct Professor Biomedical Engineering and Entrepreneurship at University of Connecticut, Brown University and Northeastern University. He has been Chairman of the board of VirtualScopics (NASDAQ: VSCP) and a member of the Board of Directors of Calando Pharmaceuticals, Inc. (known as Insert Therapeutics, Inc.), BPT Pharma, BEACON (Biomedical Engineering Alliance and CONsortium), and NanoBusiness Alliance. Providing industry leadership in the biomedical and technology fields, Dr. Analoui is actively involved in investment, management, and scientific/business development of nanotechnology, drug discovery/development, diagnostic imaging, and global strategies. Dr. Analoui has authored over 130 publications, including journal articles, book chapters, and technical reports. He holds two patents in quantitative and clinical imaging. He has received his Ph.D. from Purdue University, followed by Post-Doctoral Fellowship at IBM TJ Watson Research Center in NY.
— 30 —
Cyclica Inc. has developed, validated, patented and commercialized Ligand Express™, a cloud-based platform that screens small-molecule drugs against repositories of structurally-characterized proteins or ‘proteomes’ to determine polypharmacological profiles. Accordingly, Ligand Express™ identifies significant protein targets using an innovative structure-based and drug-centric technology, leverages artificial intelligence to determine the drug’s effect on these targets, and visualizes the predicted drug-protein interactome using bioinformatics and systems biology. The platform provides a unique panoramic view of a small-molecule, by identifying on- and off-target interactions that may be expected, as well as those that are unanticipated. By understanding how a small-molecule drug will interact with all proteins in the body, Ligand Express™ augments scientific investigation by elucidating mechanism of action, prioritizing lead candidates, understanding side effects, as well as determining new uses for existing drugs. For more information please visit: www.cyclicarx.com